Drug Information

Drug General Information
Drug ID
D0ZD6Y
Former ID
DIB003407
Drug Name
RUS 3108
Indication Atherosclerosis [ICD9: 414.0, 440; ICD10:I70] Discontinued in Phase 1 [548060]
Company
Dr. Reddy's Laboratories
Target and Pathway
Target(s) Perlecan Target Info Modulator [530972]
KEGG Pathway ECM-receptor interaction
Hepatitis B
Proteoglycans in cancer
Reactome Degradation of the extracellular matrix
Chylomicron-mediated lipid transport
A tetrasaccharide linker sequence is required for GAG synthesis
HS-GAG degradation
Integrin cell surface interactions
Laminin interactions
Non-integrin membrane-ECM interactions
Retinoid metabolism and transport
Amyloid formation
WikiPathways Visual phototransduction
Lipid digestion, mobilization, and transport
Amyloids
Extracellular matrix organization
References
Ref 548060Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021613)
Ref 530972A perlecan-inducing compound significantly inhibits smooth muscle cell function and in-stent intimal hyperplasia: novel insights into the diverse biological effects of perlecan. EuroIntervention. 2010 May;6(1):134-40.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.